Ocumetics Technology Corporation (QB) (OTCFF)

Latest news shows good progress.

https://ocumetics.com/wp-content/uploads/2025/10/Ocumetics-Reports-Encouraging-One-Month-Postoperative-Results.pdf

The 2nd set of surgeries went well, still awaiting 30 day follow-up report of 1st set.

https://money.tmx.com/quote/OTC/news/5618703358480152

Dean Burns, President and CEO of Ocumetics, commented “We are thrilled with the success of our second surgical day.”

The Company has not yet received all data from the one-month postoperative examinations of Group 1, Day 1 patients. An update will be provided when the one-month post operative results become available.

We need updates! 9/24/25 was supposed to be the 2nd set of surgeries, last week was supposed to be the 30 day follow-up report.

Latest news on human trials:

https://ocumetics.com/wp-content/uploads/2025/09/9-16-25-Ocumetics-Completes-one-month-post-op-visits.pdf

Probably the most important take away from the initial trials comes from a patient:

"...after just 1 day of surgery I can see words and colors on the walls, and I can read the information on my make up box."

Latest update by Ocumetics:

Ocumetics latest news release:

Ocumetics Prepares for a Second Day of Accommodating Intraocular Lens Implantations.

https://ocumetics.com/wp-content/uploads/2025/08/Ocumetics-Continues-FIH-surgeries.pdf

"Ocumetics Achieves Historic First: Accommodating Intraocular Lens Successfully Implanted in Human Patients"

https://ocumetics.com/wp-content/uploads/2025/08/8-18-25-Ocumetics-Completes-FIH-surgeries.pdf

Latest news release.

"We’re now just a few days away from transforming the future of vision correction with the first implantation of our groundbreaking accommodating intraocular lens."

https://ocumetics.com/wp-content/uploads/2025/08/8-12-25-Ocumetics-Achieves-Milestones.pdf

Ocumetics Begins Patent Recruitment for First-In-Human Clinical Study of Accommodating Intraocular Lens

https://ocumetics.com/wp-content/uploads/2025/08/Ocumetics-Begins-Patient-Recruitment.pdf

Ocumetcs Receives Ethics Commitee Approval for First-In-Human Clinical Study of Accommodating Intraocular Lens

https://ocumetics.com/wp-content/uploads/2025/08/Ocumetics-Receives-Ethics-Committee-Approval-for-FIH-Clinical-Study.pdf

Here's the latest news release:

https://ocumetics.com/wp-content/uploads/2025/07/Ocumetics-Announces-Completion-of-First-Tranche-of-Private-Placement.pdf

Ocumetics Announces Completion of First Tranche of Unit Private Placement
For Immediate Release
Calgary, Alberta – July 17, 2025. Ocumetics Technology Corp. (“Ocumetics” or the “Corporation”) (TSXV:
OTC) (OTCQB: OTCFF) (FRA: 2QBO) announces that it has completed the first tranche of the private
placement previously announced by the Corporation on June 4, 2025 (the “Offering”).
The Corporation has issued an aggregate of 3,212,462 units (“Units”) at a price of $0.35 per unit for
aggregate gross proceeds of $1,124,362. Each Unit consists of one common share in the share capital of
the Corporation (“Common Share”) and one-half of one common share purchase warrant. Each whole
warrant (“Warrant”) entitles the holder to purchase one additional Common Share at an exercise price of
$0.50 for a period of 24 months from the date of issuance of the Warrant.
In connection with their services as agent under the first tranche of the Offering, the Corporation paid
$68,610 to Numus Capital Corp. (“Numus Capital”) and issued to Numus Capital warrants (“Agent’s
Warrants”) entitling Numus Capital to purchase up to an aggregate of 196,029 Common Shares at a price
of $0.50 per share for a period of 24 months.
The Warrants and Agent’s Warrants are subject to an acceleration clause such that if the volume weighted
average trading price of the Common Shares on the TSX Venture Exchange is at least $0.60 per Common
Share for a period of 30 consecutive trading days, the expiry date of the Warrants may be accelerated by
the Corporation to a date that is not less than 30 days after the date that notice of such acceleration is
provided to the Warrant holders by way of a press release.
The total offering is for of up to 6,000,000 Units at a price of $0.35 per Unit for gross proceeds of up to
$2,100,000. The Corporation intends to close the rest of the offering in one or more subsequent tranches.
100% of the net proceeds are expected to be used for ongoing research and development, although the
actual allocation of proceeds may vary from the uses set out above, depending upon future operations,
events or opportunities.
All securities issued under the Private Placement are subject to a hold period of four months and one day.
Closing of the Private Placement was subject to the conditional approval from the TSX Venture Exchange,
which was obtained.

The latest:

Calgary, Alberta – July 9, 2025 - OcumeOcs Technology Corp. (“OcumeOcs” or the “Company”)
(TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO), a leader in advanced ophthalmic technology, is pleased
to announce that it has completed training of the clinical team at its first study site in Mexico
City. This training is in preparation for the upcoming first-in-human (FIH) clinical study of the
Ocumetics accommodating intraocular lens (the “Ocumetics Lens”).

https://ocumetics.com/wp-content/uploads/2025/07/7-9-25-Ocumetics-Completes-Staff-Training.pdf

https://ocumetics.com/

https://www.tipranks.com/news/company-announcements/ocumetics-launches-first-in-human-trials-for-revolutionary-intraocular-lens

Human trials begins today :)

Here's the latest video news from Ocumetics:

Just a reminder that 8 days, Jun 26th, until the human trials begin.🙂

Here is Ocumetics youtube account:

https://www.youtube.com/@Ocumetics

This is the source link for the news:

https://money.tmx.com/en/quote/OTC

The Canadian and US stock do not seem linked for news, so here is the latest:

6/4/2025: https://money.tmx.com/quote/OTC/news/7199252236063951/Ocumetics_Announces_Private_Placement

6/3/2025: https://money.tmx.com/quote/OTC/news/8620337237068400/Ocumetics_Targets_June_26_2025_for_Commencement_of_its_First_in_Human_Study

6/2/2025: https://money.tmx.com/quote/OTC/news/7884768776353010/Ocumetics_Announces_Mexico_City_as_Site_for_its_First_in_Human_Study

5/22/2025: https://money.tmx.com/quote/OTC/news/5962791226317424/Ocumetics_Clinical_Study_Protocol_Submission_and_Site_Initiation_on_Schedule_for_Summer_2025

Here’s the investor’s spill…

https://ocumetics.com/wp-content/uploads/2025/03/Ocumetics-Investor-Presentation-2025.pdf

Could not find much on this potentially life changing technology so this board is now open. This tech is an insertable permanent lens that works near and far without need of further glasses or contacts. The lens can be changed if needed in the future.

The first human trial is scheduled for June 26, 2025 in Mexico City, Mexico with I believe 15 subjects. The subjects will have both single or double implants with initial test results following after 90 days.

Current commercial applications expected in 2027 per the CEO who retired after 28 years with another optical company. He has already brought 15 products to market after going through the FDA approval process in the $6B range so he seems to have good experience in this field.

I am only a low level stock holder and have no other affiliations and probably the worst stock trader you’ll ever see on this board😂😂😂